SPECIAL REPORT
MOST SHARED
- We're Not Greece: Italian Prime Minister Monti
- Obama Likely to Call for Cutting Top Corporate Tax Rate
- To Play Senate Cybersecurity Bill, Cramer Likes Fortinet Stock
- Greek Cabinet Approves EU, IMF Bailout Bill
- Special Feature: Wall Street History - How Wall Street Got Its Name
- How to Trade the Turmoil in Greece
- Private Homebuilders: Dead Men Walking
- Why Cramer Likes Select Comfort Over Tempur-pedic Stock
- Cramer: 10 Earnings to Watch Next Week
- Lightning Round: Trina Solar, Zoltek, Affymax and More
- In Search of America's ‘Hottest Forecasters’
- Dow vs. S&P 500: Which is a Better Investment?
- Mick Fleetwood on the MP3 ‘Dumbing Down’ of Music
- Avis on the Road to Strong Growth: Analyst
- Private Homebuilders: Dead Men Walking
- LinkedIn’s Growth Is Already Priced In: Analyst
- The Real Reason Behind Bank of America’s Rally
- 5 Hedge Funds’ Top Stocks Soar After 2011 Rout
- This Valentine’s Day Love Is Served on a Silver Platter
- Greek Cabinet Approves EU, IMF Bailout Bill
- We're Not Greece: Italian Prime Minister Monti
- Private Homebuilders in the US: Dead Men Walking
- Dividend Payout Could Hit Record Amount This Year
- With Investors So Bullish, Stock Pullback Must Be Ahead
- Obama Likely to Call for Cutting Top Corporate Tax Rate
- New York Fashion Week Fall 2012
- NetNet: Why Saving Greece Could Destroy the World
- My Funny Valentine: When Love and the Fed Collide
RSS FEED
Pharma's Market
Text Size 
Analyst Eats Dendreon Crow
 |
CNBC.com |
Today he's offering a bit of a mea culpa.
Aschoff is upgrading DNDN from "Sell" to "Hold." But that's not all. Under normal circumstances I lift only brief quotes from analyst research notes for the blog or for my on-air reports. But since this one is relatively short and I know Dendreonians are gonna have a field day with this, I'm putting the whole thing on the blog.
"After more careful consideration of Dendreon's conference call, we are upgrading Dendreon to Hold from Sell due to our belief that management's bullish account of the data, despite the absence of any data presentation, will likely be justified by the data to come at the AUA conference on April 28. We find it increasingly difficult to believe that management would be that positive in a public forum, and therefore risk certain prosecution, by underdelivering at AUA due to their analyses being less than prospectively defined. We believe that Dendreon shares have an equal chance of rising or trading sideways, but we no longer see much risk of shares trading sharply lower upon presentation of the data. We also believe that there is far too much popular support for Provenge for the FDA to easily reneg on its SPA and the promise of approval should IMPACT succeed, as prospectively defined. Given the earlier results, we cannot explain how IMPACT succeeded, but we know that it does not matter as long as success was measured in a prospectively defined manner."
Wow.
Aschoff now says that his price target is "NA" or not applicable. In other words, he did not set a new one. BMC makes a market in DNDN [DNDN
Loading...
()
]and would like to bank the company.
Yeah, good luck with that.
SPA, by the way, is not a place where the FDA pampers itself. It stands for special protocol assessment which is basically an agreed-upon roadmap between the agency and a company on how to possibly win approval of a drug. IMPACT is the acronym for the Provenge study. And AUA is the American Urological Association.
What I think Aschoff is referring to is DNDN CEO Dr. Mitch Gold's repeated use of the word "unambiguous" to describe the test results. He said it on the conference call and again later in my interview with him on CNBC. He also called the data "a clear hit." I tried to pin him down on whether that meant they had met or surpassed the pre-defined threshold of showing at least a 22 percent reduction in the risk of death, but he wouldn't go there. That information will come out at AUA on the 28th.
I'll be reporting live from that meeting in Chicago where I also hope to interview Dr. Gold again shortly after researchers present the data.
Questions? Comments? and follow me on Twitter at mhuckman
Data is a real-time snapshot *Data is delayed at least 15 minutes
